Research
Hormonal
Semaglutide promotes resolution of non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis in patients with NASH and liver fibrosis.
If you have NASH, ask your doctor about Semaglutide. In clinical trials, the highest dose (0.4 mg daily) helped nearly 60% of patients resolve their liver disease without making scarring worse. It is a promising treatment for liver health.
GoodSupportsHIGH confidence
The NASH resolution was noted without worsening of fibrosis in 40% of subjects in the 0.1 mg group, 36% in the 0.2 mg group, 59% in the 0.4 mg group, and 17% in the placebo group. The difference was significant between semaglutide 0.4 mg and the placebo group.
Why this rating
Based on a Phase 2 clinical trial; Phase 3 data for NASH is less mature or not the primary focus of this specific review's headline claims.
Source
An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
Namrata Dagli et al. · Cureus · 2023
DOI 10.7759/cureus.46510
narrative_reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide 2.4 mg administered once weekly via subcutaneous injection significantly reduces body weight in adults with obesity or overweight when used as an adjunct to lifestyle modifications.Strong
- Semaglutide improves cardiovascular outcomes, including reducing the risk of major adverse cardiovascular events (MACE), in patients with type 2 diabetes.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →